Clinical Trial Update: A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating molecular changes in adults with moderate-to-severe hidradenitis suppurativa or atopic dermatiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis
• Hidradenitis Suppurativa

Drugs mentioned

• Lutikizumab (lutikizumab)

Snippet

Sponsor: AbbVie | Conditions: Hidradenitis Suppurativa, Atopic Dermatitis | Phase 2 | Status: RECRUITING